6.4 Vasoactive Medication Titration (Norepinephrine, Epinephrine, Dopamine)

6.4 Vasoactive Medication Titration

Vasoactive medications are the cornerstone of hemodynamic management in the critical care transport environment. Flight paramedics must possess a deep, pharmacology-based understanding of receptor dynamics, dosing ranges, and safety protocols to manage shock states. The selection and titration of these agents are driven by their affinity for specific adrenergic and dopaminergic receptors, which directly influence systemic vascular resistance (SVR), heart rate, and myocardial contractility.

Adrenergic and Dopaminergic Receptor Physiology

To effectively manage vasoactive infusions, transport clinicians must understand the distribution and cellular responses of the primary target receptors:

• Alpha-1 ($\alpha_1$) Receptors: Located on vascular smooth muscle. Activation triggers a $G_q$-coupled protein cascade, leading to phospholipase C activation, release of intracellular calcium, and smooth muscle contraction. This results in profound arterial and venous vasoconstriction, increasing SVR, venous return (preload), and mean arterial pressure (MAP).
• Beta-1 ($\beta_1$) Receptors: Primarily localized in the myocardium and cardiac conduction system. Activation initiates a $G_s$-coupled protein pathway, elevating cyclic adenosine monophosphate (cAMP) and activating protein kinase A. This increases calcium influx during action potentials, resulting in positive inotropy (contractility), positive chronotropy (heart rate), and positive dromotropy (conduction velocity), thereby increasing myocardial oxygen demand ($MVO_2$).
• Beta-2 ($\beta_2$) Receptors: Found in bronchial and vascular smooth muscle (especially in skeletal muscle beds). Activation leads to cAMP-mediated smooth muscle relaxation, causing bronchodilation and peripheral vasodilation, which can lower SVR.
• Dopaminergic ($D_1$ and $D_2$) Receptors: $D_1$ receptors are located in the renal, mesenteric, coronary, and cerebral vascular beds, where their stimulation causes vasodilation. $D_2$ receptors act presynaptically to inhibit norepinephrine release.

---

Norepinephrine (Levophed)

Norepinephrine is the first-line vasopressor for septic, neurogenic, and cardiogenic shock with low SVR. It functions primarily as a potent $\alpha_1$ agonist, causing vasoconstriction that elevates MAP. It also has moderate $\beta_1$ agonist activity, providing mild inotropic support, but the increase in afterload often causes a reflex bradycardia that balances the chronotropic effect.

• Dosing: Standard titration ranges from 0.01 to 3.0 mcg/kg/min. In non-weight-based protocols, it is initiated at 2 to 5 mcg/min and titrated up to 30 mcg/min.
• Clinical Implications: Norepinephrine increases both venous and arterial tone. Venoconstriction shifts blood from the splanchnic circulation to the central compartment, increasing preload, while arterioloconstriction increases SVR. This dual mechanism effectively restores organ perfusion pressure in vasodilatory states without excessively increasing heart rate, reducing the risk of tachyarrhythmias compared to other agents.

---

Epinephrine (Adrenaline)

Epinephrine is a non-selective, potent agonist of $\alpha_1$, $\beta_1$, and $\beta_2$ receptors. It is the drug of choice for anaphylaxis, severe post-cardiac arrest shock, symptomatic bradycardia refractory to atropine/pacing, and refractory septic shock.

• Dosing: Hemodynamic infusions are typically titrated from 0.01 to 0.2 mcg/kg/min (or 2 to 10 mcg/min). Anaphylaxis doses are 0.3 mg IM (1:1,000) for standard emergencies, or 5 to 20 mcg IV boluses for peri-arrest states.
• Biphasic Hemodynamic Actions: Epinephrine demonstrates distinct dose-dependent receptor affinities:
  • Low Doses (0.01–0.05 mcg/kg/min): $\beta_1$ and $\beta_2$ adrenergic effects dominate. Cardiac output rises due to increased heart rate and contractility, while SVR may decrease or remain neutral because of $\beta_2$-mediated vasodilation.
  • High Doses (> 0.05 mcg/kg/min): $\alpha_1$ receptor stimulation overcomes $\beta_2$ vasodilation. This leads to marked systemic vasoconstriction, rapid increases in SVR, MAP, and myocardial workload, along with persistent $\beta_1$-mediated tachycardia.
• Adverse Metabolic Effects: Epinephrine stimulates skeletal muscle $\beta_2$ receptors, which accelerates aerobic glycolysis and increases lactate production (hyperlactatemia). This occurs independently of tissue hypoxia and can lead to a misleading lactic acidosis, which clinicians must distinguish from worsening perfusion.

---

Dopamine

Dopamine is a precursor to norepinephrine and epinephrine. While its clinical use has significantly declined due to the risk of tachyarrhythmias and increased mortality in cardiogenic shock (demonstrated in the SOAP II trial), it remains highly tested on transport exams.

• Dose-Dependent Receptor Activation:
  • Low Dose (1–5 mcg/kg/min - "Renal Dose"): Stimulates $D_1$ and $D_2$ receptors, inducing vasodilation in the renal, mesenteric, and coronary beds. Note: Clinical trials have disproven that this prevents renal failure, but the physiological concept is tested.
  • Intermediate Dose (5–10 mcg/kg/min - "Inotropic Dose"): Stimulates $\beta_1$ receptors. This promotes myocardial contractility, increases heart rate, and stimulates the release of endogenous norepinephrine, enhancing cardiac output.
  • High Dose (10–20 mcg/kg/min - "Vasopressor Dose"): Stimulates $\alpha_1$ receptors, resulting in systemic vasoconstriction and elevated SVR. Doses exceeding 20 mcg/kg/min produce intense vasoconstriction resembling pure alpha agonists, but with severe arrhythmogenic side effects.

---

Extravasation and Tissue Necrosis Management

Vasoactive medications administered through a peripheral IV carry a high risk of extravasation. The intense local $\alpha_1$ stimulation causes severe vasoconstriction, leading to localized ischemia, hypoxia, and tissue necrosis.

• Prevention: Central venous catheters (CVC) are preferred. If peripheral access must be used, utilize a large-bore IV (18G or larger) in a large proximal vein (e.g., antecubital fossa), confirm patency frequently, and limit infusion duration to under 12–24 hours.
• Active Extravasation Protocol:
  1. Stop the infusion immediately. Do not flush the line.
  2. Do not remove the IV catheter. Attach a syringe and aspirate as much residual drug from the catheter hub as possible.
  3. Administer the antidote: Phentolamine (Regitine). Phentolamine is a competitive, non-selective alpha-adrenergic receptor antagonist that reverses local vasoconstriction.
     • Dosing & Preparation: Dilute 5 to 10 mg of phentolamine in 10 to 15 mL of 0.9% normal saline.
     • Administration: Inject the solution subcutaneously/intradermally directly through the IV catheter (if still patent) and then infiltrate the remaining solution in a circular pattern around the blanched, ischemic area using a fine-gauge needle (25G or 27G). This must be done within 12 hours of the event to prevent tissue sloughing.
     • Alternatives: If phentolamine is unavailable, topical 2% nitroglycerin paste or terbutaline infiltration can be used to promote vasodilation.

Physiological Considerations: pH and Catecholamine Responsiveness

Severe acidemia (pH < 7.2) significantly blunts the hemodynamic effectiveness of catecholamines. An abundance of hydrogen ions alters the tertiary structure of adrenergic receptors and uncouples G-proteins from their intracellular signaling pathways. In cases of refractory shock with profound metabolic or respiratory acidosis, the underlying acid-base balance must be corrected (via ventilation optimization or targeted buffer therapy, when indicated) to restore the efficacy of circulating vasopressors.